There may soon be another option for an Alzheimer’s drug capable of slowing the progression of the devastating disease.
An experimental Alzheimer’s drug from drugmaker Eli Lilly helped slow cognitive decline in patients in the early stages of the illness, according to the results of a late-stage clinical trial. Side effects of the drug, called donanemab, however, were serious in some cases, and included brain swelling and brain bleeds.
Lilly representatives presented the results at the Alzheimer’s Association International Conference in Amsterdam on Monday. The research was published simultaneously in the Journal of the American Medical Association.
Leave a reply